Skip to content
Triangle logo TriangleGet started
← Study library

NCT01894477 · REGISTRY CONDITION SEARCH

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
UNKNOWN
Registry last update
2021-06-03

This randomized phase II trial studies how well treosulfan and fludarabine phosphate, with or without total body irradiation before donor stem cell transplant works in treating patients with myelodysplastic syndrome or acute myeloid leukemia. Giving chemotherapy, such as treosulfan and fludarabine phosphate, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus before and mycophenolate mofetil after the transplant may stop this from happening.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants That Did Not Progress Within 6 Months

→

outcome · POSTED

Number of Participants With Acute GVHD, Graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

→

outcome · NOT POSTED

Incidence of Chronic GVHD Graded by the NCI CTCAE Version 4.0

→

outcome · NOT POSTED

Incidence of Relapse/Progression

→

outcome · NOT POSTED

NRM

→

outcome · NOT POSTED

Overall Survival (OS)

→

outcome · NOT POSTED

Change in Gene Expression Profiles

→

outcome · NOT POSTED

Relapse Risk as Measured by Degree of Change in Gene Expression Profiles

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * MDS, myelodysplastic syndrome/myeloproliferative neoplasia overlap disorders (including chronic myelomonocytic leukemia \[CMML\], and MDS/myeloproliferative neoplasm \[MPN\] unclassifiable syndromes) * AML, other than acute promyelocytic leukemia (APL), in first or second remission or with minimal residual disease * With Karnofsky index or Lansky Play-Performance scale \> 70% on pre-transplant evaluation * Able to give informed consent (if \> 18 years), or with a legal guardian capable of giving informed consent (if \< 18 years) * Patients with previous autologous or allogeneic HCT are allowed to enroll * DONOR: Human leukocyte antigen (HLA)-identical related donors or * DONOR: Unrelated donors matched for HLA-A, B, C, DRB1, and DQB1 as defined by high resolution deoxyribonucleic acid (DNA) typing; mismatch for one HLA allele is allowed * DONOR: Donors able to undergo peripheral blood stem cell collection or bone marrow harvest * DONOR: Donors in good general health, with a Karnofsky or Lansky play performance score \> 90% * DONOR: Donors able to give informed consent (if \> 18 years), or with a legal guardian capable of giving informed consent (if \< 18 years) Exclusion Criteria: * Receiving umbilical cord blood * With impaired cardiac function as evidenced by ejection fraction \< 35% (or, if unable to obtain ejection fraction, shortening fraction of \< 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction \< 26% may be enrolled if approved by a cardiologist * With impaired pulmonary function as evidenced by partial pressure of oxygen (pO2) \< 70 mm Hg and carbon monoxide diffusing capability test (DLCO) \< 70% of predicted or pO2 \< 80 mm Hg and DLCO \< 60% of predicted; (or, for pediatric patients unable to perform pulmonary function tests, then oxygen (O2) saturation \< 92% on room air), or receiving supplementary continuous oxygen * With impaired renal function as evidenced by creatinine-clearance \< 50% for age, weight, height or serum creatinine \> 2 x upper limit of normal or dialysis-dependent * With hepatic dysfunction as evidenced by total bilirubin \> 2.0 x upper limit of normal or evidence of synthetic dysfunction or severe cirrhosis * With hepatic dysfunction as evidenced by aspartate aminotransferase (AST) \> 2.0 x upper limit of normal or evidence of synthetic dysfunction or severe cirrhosis * With active infectious disease requiring deferral of conditioning, as recommended by an infectious disease specialist * With human immunodeficiency virus (HIV)-positivity or active infectious hepatitis * With central nervous system (CNS) leukemic involvement not clearing with intrathecal chemotherapy, cranial irradiation or both prior to initiating conditioning (day -6) * Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies who have been rendered with no evidence of disease, but have a greater than 20% chance of having disease recurrence within 5 years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy * With life expectancy severely limited by diseases other than malignancy * Women who are pregnant or lactating * With known hypersensitivity to treosulfan or fludarabine (fludarabine phosphate) * Receiving another experimental drug within 4 weeks before initiation of conditioning (day -6) * Unable to give informed consent (if \> 18 years) or with a legal guardian (if \< 18 years) unable to give informed consent * DONOR: Individuals deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis * DONOR: Individuals who are HIV-positive * DONOR: Individuals with active infectious hepatitis * DONOR: Females with a positive pregnancy test * DONOR: Persons unable to give informed consent (if \> 18 years) or with a legal guardian (if \< 18 years) unable to give informed consent
healthy Volunteers
false
maximum Age
70 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Arm A: Treosulfan, Fludarabine Phosphate Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
    intervention Names
    1. Procedure: Allogeneic Bone Marrow Transplantation
    2. Drug: Fludarabine Phosphate
    3. Procedure: Peripheral Blood Stem Cell Transplantation
    4. Radiation: Total-Body Irradiation
    5. Drug: Treosulfan
    6. Other: Laboratory Biomarker Analysis
    label
    Arm A
    type
    EXPERIMENTAL
  2. description
    Arm B: Treosulfan, Fludarabine Phosphate, TBI Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0
    intervention Names
    1. Procedure: Allogeneic Bone Marrow Transplantation
    2. Drug: Fludarabine Phosphate
    3. Procedure: Peripheral Blood Stem Cell Transplantation
    4. Drug: Treosulfan
    5. Other: Laboratory Biomarker Analysis
    label
    Arm B
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm A
    2. Arm B
    description
    Undergo allogeneic bone marrow transplant
    name
    Allogeneic Bone Marrow Transplantation
    other Names
    1. Allo BMT
    2. Allogeneic BMT
    type
    PROCEDURE
  2. arm Group Labels
    1. Arm A
    2. Arm B
    description
    Intravenously administered Fludarabine Phosphate
    name
    Fludarabine Phosphate
    other Names
    1. 2-F-ara-AMP
    2. Beneflur
    3. Fludara
    4. SH T 586
    type
    DRUG
  3. arm Group Labels
    1. Arm A
    2. Arm B
    description
    Undergo allogeneic PBSC transplant
    name
    Peripheral Blood Stem Cell Transplantation
    other Names
    1. PBPC transplantation
    2. Peripheral Blood Progenitor Cell Transplantation
    3. Peripheral Stem Cell Support
    4. Peripheral Stem Cell Transplantation
    type
    PROCEDURE
  4. arm Group Labels
    1. Arm A
    description
    Undergo TBI
    name
    Total-Body Irradiation
    other Names
    1. TOTAL BODY IRRADIATION
    2. Whole-Body Irradiation
    type
    RADIATION
  5. arm Group Labels
    1. Arm A
    2. Arm B
    description
    Intravenously administered Treosulfan
    name
    Treosulfan
    other Names
    1. 1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-
    2. Dihydroxybusulfan
    3. Ovastat
    4. Treosulphan
    5. Tresulfon
    type
    DRUG
  6. arm Group Labels
    1. Arm A
    2. Arm B
    description
    Correlative Studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
102
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Progression is defined as relapse
    measure
    Number of Participants That Did Not Progress Within 6 Months
    time Frame
    At 6 months post-transplant
secondary Outcomes
  1. measure
    Number of Participants With Acute GVHD, Graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
    time Frame
    Up to 84 days
  2. measure
    Incidence of Chronic GVHD Graded by the NCI CTCAE Version 4.0
    time Frame
    Up to 5 year
  3. measure
    Incidence of Relapse/Progression
    time Frame
    Up to 5 year
  4. measure
    NRM
    time Frame
    Up to 5 years
  5. measure
    Overall Survival (OS)
    time Frame
    Up to 2 year
  6. description
    Differences between arms in the changes in gene expression will be compared. 80% power to detect mean differences of approximately 1.4 standard deviation units, at the 2-sided 0.05 level of significance (with Bonferroni correction for 50 genes).
    measure
    Change in Gene Expression Profiles
    time Frame
    Baseline and at day 0 within 6 hours of conditioning prior to transplant
  7. description
    Among genes identified whose expression is modified by conditioning, degree of change in expression will be evaluated to determine if it is correlated with relapse risk and offers improved prediction of relapse risk over that obtained with standard clinical parameters (cytogenetics, blast count, International Prognostic Scoring System score, minimal residual disease. To account for censoring and the competing risk of non-relapse mortality (NRM), the analysis will be a time-to-event analysis of relapse using Cox regression, with change in expression as a continuous covariate (on a log scale). 8
    measure
    Relapse Risk as Measured by Degree of Change in Gene Expression Profiles
    time Frame
    Baseline and at day 0 within 6 hours of conditioning prior to transplant
Full study description
brief Summary
This randomized phase II trial studies how well treosulfan and fludarabine phosphate, with or without total body irradiation before donor stem cell transplant works in treating patients with myelodysplastic syndrome or acute myeloid leukemia. Giving chemotherapy, such as treosulfan and fludarabine phosphate, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus before and mycophenolate mofetil after the transplant may stop this from happening.
detailed Description
PRIMARY OBJECTIVES: I. To determine the better of two treosulfan-based conditioning regimens in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), by comparing 6-month progression-free survival. SECONDARY OBJECTIVES: I. Determine the effects of two conditioning regimens on changes in gene expression profiles, and evaluate the association of gene expression profiles and disease relapse. II. Determine the incidence of progression-free survival at 1 year and 2 years after hematopoietic cell transplantation (HCT). III. Evaluate overall survival (OS) at 6 months, at 1 year and at 2 years after HCT. IV. Determine the incidence of grades II-IV acute graft-versus-host disease (GVHD). V. Determine the incidence of chronic GVHD. VI. Determine donor chimerism around days +28 and +84. CONDITIONING REGIMEN: Arm A: Patients receive treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2. Arm B: Patients receive treosulfan and fludarabine phosphate as in Arm A and undergo low-dose total-body irradiation (TBI) on day 0. TRANSPLANT: Patients in both arms undergo allogeneic peripheral blood stem cell (PBSC) transplant or bone marrow transplant on day 0. GVHD PROPHYLAXIS: Patients with a related donor receive tacrolimus orally (PO) every 8 or 12 hours on days -3 to 56 with taper to day 180. Beginning 4-6 hours after PBSC infusion, patients also receive mycophenolate mofetil PO every 12 hours to day 28. Patients with an unrelated donor receive tacrolimus PO every 8 or 12 hours on days -3 to 100 with taper to day 180. Beginning 4-6 hours after PBSC infusion, patients also receive mycophenolate mofetil PO every 8 hours to day 40 with taper to day 96. NOTE: Patients with related donors eligible for FHCRC protocol 2545 may receive cyclosporine IV, instead of tacrolimus, beginning on day -3 to day 50 with a taper to day 180. After completion of study treatment, patients are followed up periodically.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-16ba349b6b48188e9de4
      requested nct id
      NCT01894477
      primary nct id
      NCT01894477
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      payload sha256
      ae460a26fde475ee29e99f6f69cb21ac233e898bc708127c9e6a7f516c2c97a3
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-16ba349b6b48188e9de4
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01894477
      occurrences
      1. context exact
        NCT01894477
        end
        11
        exact text
        NCT01894477
        start
        0
      offset unit
      unicode_code_points
      query cond
      Juvenile Myelomonocytic Leukemia
      query disease state id
      ds-juvenile-myelomonocytic-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      source json pointer
      /studies/146/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      051160c11bdf91ec6d5aa03e7254cda386eb8351e876c159770094c36fc06b6b

    Preserved source evidence · Not medical advice